SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
- Written by PR Newswire
![]() |
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board
BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual...
Read more: SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting















